Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S274.
doi: 10.21037/atm.2019.11.150.

Before it catches the eye…

Marian J Mourits  1 , Geertruida H de Bock  2
Affiliations
Editorial

Before it catches the eye…

Marian J Mourits et al. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

References

    1. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018;68:284-96. 10.3322/caac.21456 - DOI - PMC - PubMed
    1. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006;24:863-71. 10.1200/JCO.2005.03.6772 - DOI - PMC - PubMed
    1. Peres LC, Cushing-Haugen KL, Kobel M, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst 2019;111:60-8. 10.1093/jnci/djy071 - DOI - PMC - PubMed
    1. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016;387:945-56. Erratum in: Lancet 2016;387:944. 10.1016/S0140-6736(15)01224-6 - DOI - PMC - PubMed
    1. Hermsen BB, Olivier RI, Verheijen RH, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Brit J Cancer 2007;96:1335-42. 10.1038/sj.bjc.6603725 - DOI - PMC - PubMed